

THE UNITED STATES PATENT AND TRADEMARK OFFICE

ication of:

BIGGADIKE, Keith

Serial No.:

10/066,964

Group Art Unit:

Filed:

C. []

04 February 2002

Examiner:

TECH CENTER 1600/2900

For: FORMULATION CONTAINING NOVEL-ANTI INFLAMMATORY ANDROSTANE DERIVATIVE

Commissioner for Patents Washington, D.C. 20231

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[] [X]	Copies of the references are enclosed:  Copies of the references were submitted in parent application Serial No09/958,050 (37 CFR 1.98(d))  A copy of the International Search Report which issued on International Application Nois submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.						
Α.	[X]	the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
		The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).						
B.	EJ	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first.						
	[] Applicant hereby certifies that each item of information contained in this Information Disclosur Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.							
		Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).						

The Information Disclosure Statement transmitted herewith is being filed after a final action under §

1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the



issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Attorney of Record: James P. Riek

26 Av , 2002

Registration No. 39,009

GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8022 Facsimile: (919) 483-7988

23347

PATENT TRADEMARK OFFICE

**CERTIFICATE OF MAILING (37 CFR 1.8)** 

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown beiew with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents, Washington, D.C. 20231.

L'ate: 8/26/02

Ban Youna

FORM PTO			CAMED ARKING		ATIORNEY DOCKET NO.   SERIAL NO.			
INFURIVIA	A E	DESCLOSURE ST	TATEMENT		PG4709 10/066,964 APPLICANT			
1 /	00	, part			BIGGADIKE, Keith			
1 /	2)	JULI HE			FILING DATE GROUP			
] {	40 6	23 8			04 Feb 2002 ·		GROOL	
	<del>_</del> \$>_		U.S. I	PATENT DO	OCUMENTS			<del>-</del>
	PRIT	Ta TRIA		I			1	Filing Date
Examiner Initials	7.0	I accine	Issue Date		Name	Class	Subclass	If Appropriate
Initizis	<u> </u>	Number	<u> </u>	<u> </u>				Appropriate
	——			<u> </u>				
	<b> </b>	<del> </del>		ļ				
	<del> </del>		<del> </del>				RECEN	AED
· · · · · ·	<del> </del>		<del> </del>				WEOFIA	
	├		ļ	ļ			10500	, nn2
	<del> </del>		<u> </u>	<b>ļ</b>			SEP 0 9 2	1002
	<del> </del>	<del> </del>		<b>ļ</b>			<del> </del>	100000
	<del> </del>	<del> </del>	<del></del>	<del>                                     </del>		75	CH CENTER	160015300
	Щ	L	<u> </u>	<u> </u>		15	,011 0211.	<u> </u>
	I —	T*****	T	1		<del>-</del>	<del>1</del>	Translation
		/				Class	Subclass	Yes   No
				<del>                                     </del>			- Subclass	
							<del> </del>	<del> </del>
				<del>                                     </del>				
							COPYOFF	
•						-1	ORIGINALLY	FILED
-						<del>-</del>		
				ontinue on p				
					Title, Journal-Date,			
	CB				IS MORE EFFECTI			
					ASTHMA WHO AR			
		FLUTICASONE,	"European Resp	ratory Revi	ew, Copenhagen, DK	, vol 12, no. S	SUPPL 29, Deco	ember 1998
		(1998-12), pages			OTERC OF CORTIC	OCCEP OTDO	O 11 DETAIL	VDBOVV
CC Shapiro, E.L., et. al., "17 HETEROAROYL ESTERS OF CORTICOSTEROIDS 2. 11-BETA HYDROX								
SERIES," Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 30, no. 9, 1987, pages 1581-1588, XP002153839								
		ison, pages tool	1500, 112 002155					
			<del></del>					
			C	ontinue on p	age			
EXAMINER						DATE CO	ONSIDERED	
					s in conformance with			